Rahul Singhvi, Resilience CEO

Re­silience starts the year with its first deal out­side of North Amer­i­ca

Man­u­fac­tur­ing com­pa­ny Re­silience hit sev­er­al high points in 2022 in se­cur­ing an­oth­er fund­ing round and net­ting part­ner­ships with ma­jor play­ers, and now it’s start­ing the new year with a deal that moves it out­side North Amer­i­ca for the first time.

On Tues­day, Re­silience an­nounced that the Abu Dhabi-based sov­er­eign in­vestors, the Mubadala In­vest­ment Com­pa­ny, inked an eq­ui­ty in­vest­ment. The two par­ties will col­lab­o­rate on a bio­phar­ma man­u­fac­tur­ing plan to build a new man­u­fac­tur­ing fa­cil­i­ty in Abu Dhabi. As per the deal, Mubadala will es­tab­lish the fa­cil­i­ty and Re­silience will op­er­ate it. The Abu Dhabi fa­cil­i­ty will man­u­fac­ture a range of prod­ucts, in­clud­ing ther­a­pies for can­cer and in­fec­tious dis­eases, along with vac­cines and oth­er prod­ucts.

Re­silience will pro­vide the man­u­fac­tur­ing along with the tech­nol­o­gy and “ex­per­tise,” and in­cor­po­rate it in­to its glob­al net­work and giv­ing the com­pa­ny a foothold in the Mid­dle East. The ex­act de­tails of where the fa­cil­i­ty will be lo­cat­ed, along with the size and time­line for com­ple­tion, were not dis­closed.

“This will be Re­silience’s first man­u­fac­tur­ing fa­cil­i­ty out­side of North Amer­i­ca, a sig­nif­i­cant mile­stone for the com­pa­ny, rep­re­sent­ing that Re­silience is seen as a trust­ed part­ner who will bring ad­vanced bio­man­u­fac­tur­ing tech­nolo­gies and op­er­at­ing sys­tems to the re­gion. This will al­low the re­gion to be­come self-suf­fi­cient and re­silient to changes,” said Re­silience CEO Rahul Singhvi, in an emailed state­ment to End­points News.

The specifics of the fi­nan­cial in­vest­ment were al­so not dis­closed, but Singhvi said Mubadala had in­vest­ed in mul­ti­ple rounds of eq­ui­ty fi­nanc­ing at Re­silience and that this Mubadala in­vest­ment is in­clud­ed in the “ag­gre­gate round sizes” that have been pre­vi­ous­ly an­nounced. Singhvi al­so not­ed that some of the board mem­bers of Re­silience have a pri­or re­la­tion­ship with Mubadala. Re­silience raised $625 mil­lion in a Se­ries D in June of last year.

“Through this agree­ment, Mubadala and its group com­pa­nies will un­lock fur­ther op­por­tu­ni­ties for growth with­in the life sci­ences ecosys­tem, and along­side our key part­ners, will play an in­stru­men­tal role in es­tab­lish­ing a state-of-the-art bio­phar­ma cam­pus that will se­cure the re­gion’s sup­ply chain from Abu Dhabi,” said Badr Al-Ola­ma the ex­ec­u­tive di­rec­tor of UAE Clus­ters at Mubadala, in a state­ment.

Abu Dhabi has been work­ing to boost phar­ma man­u­fac­tur­ing in the coun­try. In late De­cem­ber, As­traZeneca and Abu Dhabi-based G42 Health­care inked a strate­gic man­u­fac­tur­ing deal to make drugs in Abu Dhabi. That man­u­fac­tur­ing deal will fo­cus on R&D and “lo­cal­iz­ing” in­dus­tries to pro­duce phar­ma prod­ucts, as As­traZeneca al­so has “on­go­ing ef­forts” with the De­part­ment of Health of Abu Dhabi. Abu Dhabi al­so has un­veiled plans to dou­ble the size of its man­u­fac­tur­ing sec­tor by 2031.

Re­silience spent last year ce­ment­ing its pres­ence in North Amer­i­ca. In No­vem­ber, it pur­chased an As­traZeneca man­u­fac­tur­ing fa­cil­i­ty in West Chester, OH, just north of Cincin­nati. Re­silience will pro­duce “se­lect” As­traZeneca med­i­cines at the fa­cil­i­ty as part of the sup­ply agree­ment.

Am­gen lays off about 300 work­ers, cit­ing 'in­dus­try head­wind­s'

Amgen has laid off about 300 employees, a company spokesperson confirmed to Endpoints News via email Sunday night.

Employees posted to LinkedIn in recent days about layoffs hitting Amgen last week. The Thousand Oaks, CA-based biopharma, which employs about 24,000 people, said the reduction “mainly” impacted US-based workers on its commercial team.

Drug developers of all sizes, including small upstarts and pharma giants, have let employees go in recent months as the biopharma market drags through a quarters-long winter doldrum.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bob Bradway, Amgen CEO (Stephen Lam/Reuters)

Am­gen launch­es the first US Hu­mi­ra biosim­i­lar at two dif­fer­ent list prices

The bizarre dynamics of the US prescription drug market were on full display once again this morning as Amgen announced that it would launch the first US biosimilar for Humira, the best-selling drug of all time, at two completely different list prices.

One price for Amgen’s Amjevita (adalimumab-atto) will be 55% below the current Humira list price, which is about $84,000 per year, and another at a list price 5% below the current Humira list price, but presumably (pharma companies don’t disclose rebates) with high rebates to attract PBMs and payers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Dirk Thye, Quince Therapeutics CEO

Af­ter piv­ot­ing from Alzheimer's to bone con­di­tions, biotech piv­ots again — and halves its head­count

When troubled public biotech Cortexyme bought a private startup named Novosteo and handed the keys to its executive team, the company — which changed its name to Quince Therapeutics — said it would shift its focus from an unorthodox Alzheimer’s approach to Novosteo’s bone-targeting drug platform.

Less than a year later, Quince is pivoting again.

The biotech has decided to out-license its bone-targeting drug platform and its lead drug, NOV004, and instead look for clinical-stage programs to in-license or acquire, according to a press release.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Credit: Shutterstock

New York City in­vests $20M in­to biotech 'in­no­va­tion space' at the Brook­lyn Navy Yard

New York City is investing $20 million in biotech this year in the form of a 50,000-square-foot “innovation space” at the Brooklyn Navy Yard, complete with offices, research laboratories and events and programming space to grow biotech startups and companies.

Mayor Eric Adams said during his State of The City Address last Thursday that there will be an “emphasis” on making more opportunities for women and people of color to further diversify the industry. The City first reported the news.

Charles Riv­er se­cures $50M ac­qui­si­tion of drug dis­cov­ery tech com­pa­ny

Over the past several years, Massachusetts-based contractor Charles River Laboratories has been busy on the M&A front, with the latest, $50 million buyout coming Monday for a provider of high-throughput screening solutions for discovery research.

Chicago-based SAMDI Tech will now be folded into Charles River’s discovery and safety assessment division, Charles River announced.

The $50 million in cash is for the 80% of SAMDI that Charles River didn’t previously own. Other financial details on the deal were not disclosed.

Boehringer In­gel­heim touts pre­ven­tion re­sults in rarest form of pso­ri­a­sis

Boehringer Ingelheim uncorked some positive results suggesting that Spevigo can help prevent flare-ups in patients with a severe form of psoriasis, months after the drug was approved to treat existing flares.

Spevigo, an IL-36R antibody also known as spesolimab, met its primary and a key secondary endpoint in the Phase IIb EFFISAYIL 2 trial in patients with generalized pustular psoriasis (GPP), Boehringer announced on Monday. While the company is keeping the hard numbers under wraps until later this year, it said in a news release that it anticipates sharing the results with regulators.

As­traZeneca, No­vo Nordisk and Sanofi score 340B-re­lat­ed ap­peals court win over HHS

AstraZeneca, Novo Nordisk, and Sanofi won an appeals court win on Monday, as the US Court of Appeals for the Third Circuit found that the companies cannot be forced to provide 340B-discounted drugs purchased by hospitals from an unlimited number of community and specialty pharmacies.

“Legal duties do not spring from silence,” the decision says as the court makes clear that the federal government’s interpretation of the “supposed requirement” that the 340B program compels drugmakers to supply their discounted drugs to an unlimited number of contract pharmacies is not correct, noting:

Ap­peals court toss­es J&J's con­tro­ver­sial 'Texas two-step' bank­rupt­cy case

A US appeals court has ruled against Johnson & Johnson’s use of bankruptcy to deal with mounting talc lawsuits, deciding that doing so would “create a legal blind spot.”

The Third Circuit Court of Appeals reversed a previous bankruptcy court decision on Monday, calling for the dismissal of a Chapter 11 filing by J&J’s subsidiary LTL Management.

Faced with more than 38,000 lawsuits alleging its talc-based products caused cancer, J&J spun its talc liabilities into a separate company called LTL Management back in October 2021 and filed for bankruptcy, a controversial move colloquially referred to as a “Texas two-step” bankruptcy. Claimants argued that the strategy is a misuse of the US bankruptcy code — and on Monday, a panel of judges agreed.

Chad Mirkin, Flashpoint co-founder

‘The field is at a flash­point’: New Chad Mirkin-found­ed biotech hopes to make more ef­fec­tive can­cer vac­cines

Following the success of the mRNA Covid vaccines, cancer vaccines are seeing renewed interest after years of middling results. But a group of researchers suggests that more attention needs to be paid not to what goes into those vaccines, but how the parts are put together.

In a recent paper published in Nature Biomedical Engineering, researchers led by Northwestern University’s Chad Mirkin describe how the placement of different antigens in a cancer vaccine impacts its efficacy. The paper builds on past work done by Mirkin’s lab that suggests the structure, or how the parts of a vaccine are arranged, impact a vaccine’s efficacy, not just its components.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.